US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Diagnostic Medical Systems (0RIA) 銘柄情報

Diagnostic Medical Systems (0RIA)

1.39

0.00

(0.00%)

終了 7月13日 12:30AM

Diagnostic Medical Systems (0RIA) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

1.39

( - )

買値

1.39

売値

1.39

出来高

0.00

平均取引量 (3 か月)

12,477 €

財務取引量

-

0.00 日の範囲 0.00

1.39 52 週間の範囲 1.39

時価総額

企業価値

45.246M

前日終値

1.39

始値

-

時刻

最終取引時間

VWAP

-

歳入

52.86M

純利益

-167k

発行済株式数

25,915,254

浮動株比率 (%)

52.92%

機関投資家保有比率 (%)

39.65%

配当利回り

PER

-124

株価売上高倍率 (PSR)

0.61

1 株当たり利益 (EPS)

-0.01

ベータ

0.7

Diagnostic Medical Systems S.A. designs, develops, manufactures, and sells medical imaging systems in France. The company offers ADAM, a software suite for imaging experts; R and F solutions, including Platinum Neo, Platinum Flex, and Optima; bone densitometers, including Stratos and Medix Series; M... Diagnostic Medical Systems S.A. designs, develops, manufactures, and sells medical imaging systems in France. The company offers ADAM, a software suite for imaging experts; R and F solutions, including Platinum Neo, Platinum Flex, and Optima; bone densitometers, including Stratos and Medix Series; MISTRAL, a manual chest and bone solution; and Camargue series which offers motorized radiographic systems to perform all types of bone and chest exams, including full spine and long leg exams. It also provides mobiles under the !M1, ONYX, Rafale/Rafale DR, and !Mobile Wall Stand names; c-arm products under the EVO R+ FP ADAM and EVO + / EVO R+ names; retrofit kits; and mammography equipment. The company was founded in 1979 and is headquartered in Gallargues-le-Montueux, France. 詳細を表示

セクター

Health Care

業界

Health Care Equipment & Supplies

ウェブサイト

www.dms-imaging.com

本社

Gallargues-le-montueux, France

設立

1979

Diagnostic Medical Systems is listed in the Health Care sector of the ロンドン証券取引所 with ticker 0RIA. The last closing price for Diagnostic Medical Systems was 1.39 €. Over the last year, Diagnostic Medical Systems shares have traded in a share price range of 1.39 € to 1.39 €.

Diagnostic Medical Systems currently has 25,915,254 shares in issue. The market capitalisation of Diagnostic Medical Systems is 36.02 € million. Diagnostic Medical Systems has a price to earnings ratio (PE ratio) of -124.00.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	1.39	1.39	1.39	34	1.39	DE
52	0	0	1.39	1.39	1.39	123	1.39	DE
156	0	0	1.39	1.39	1.39	39	1.39	DE
260	0	0	1.39	1.39	1.39	23	1.39	DE

0RIA - Frequently Asked Questions (FAQ)

What is the current Diagnostic Medical Systems share price?

The current share price of Diagnostic Medical Systems is 1.39 €

How many Diagnostic Medical Systems shares are in issue?

Diagnostic Medical Systems has 25,915,254 shares in issue

What is the market cap of Diagnostic Medical Systems?

The market capitalisation of Diagnostic Medical Systems is EUR 36.02M

What is the 1 year trading range for Diagnostic Medical Systems share price?

Diagnostic Medical Systems has traded in the range of 1.39 € to 1.39 € during the past year

What is the PE ratio of Diagnostic Medical Systems?

The price to earnings ratio of Diagnostic Medical Systems is -124

What is the cash to sales ratio of Diagnostic Medical Systems?

The cash to sales ratio of Diagnostic Medical Systems is 0.61

What is the registered address of Diagnostic Medical Systems?

The registered address for Diagnostic Medical Systems is 9 Avenue du Canal Philippe Lamour, Gallargues-le-Montueux, Languedoc-Roussillon, 30 660

What is the Diagnostic Medical Systems website address?

The website address for Diagnostic Medical Systems is www.dms-imaging.com

Which industry sector does Diagnostic Medical Systems operate in?

Diagnostic Medical Systems operates in the Health Care Equipment & Supplies sector

Truthsocial

Truthsocial 1分前

Yes, preliminary trial results for Vivos Inc (RDGL) in India are available and have been publicly reported, but comprehensive final data is still pending.

Safety and Efficacy Data: Reports from early 2025 confirm that ten patients with cancerous lymph nodes were successfully treated

Biotech_Tradez

Biotech_Tradez 4分前

Heard Electrome was not happy with Mayer on a number of different fronts.

They were not very keen on this deal with BIEL because it is a distraction from what they are doing with their own patent-pending device that was invented by the new CEO. He is taking it to DARPA for funding. On

shajandr

shajandr 12分前

SAM ALTMAN = LIZZY HOLMES with better hair.

ron_66271

ron_66271 14分前

The Discovery Document by QE Proves RICO.

Project West.

The BOD was reviewed on the status of the project three times from the discovery document.
Therefore the BOD past and present are compliant if current members have not voiced their concerns about settlement

Porch Honkey

Porch Honkey 17分前

When they are ready, there will be investors here that you have never seen before, gl.

LOB

Blaqclouds Wyoming

@blaqclouds_WY
#Blaqclouds • #DEFI💎 http://BLAQpay.io http://AplloNFT.io🔎• #NFT #WEB3 Dev • DM 📩 for Collab
Social Media InfluencerPAblaqclouds.io
Joined May 2020
1,260 Following
123.5K Followers

Juststoppingby

Juststoppingby 22分前

My AI responds to clarification on “EDGAR packages are being validated”.

When I say “EDGAR packages are being validated,” I’m talking about a very specific, very technical stage in the SEC-filing process — one that happens right before a delinquent filer begins submitting forms.

zakattack

zakattack 23分前

They put out a pr dec 2025 stating they would increase to 49% in gncp but no filings proving they actually did so sp again where is the proof pdiv paid anything or did anything for the land claims prove me wrong

nowwhat2

nowwhat2 27分前

xxxxxxxxxxxx wow

https://investorshub.advfn.com/uimage/uploads/2026/7/13/i[smibtc_july_12_2m_7pm_200_64_diag_point.jpg

https://investorshub.advfn.com/uimage/uploads/2026/7/13/wtzkebtc_july_12_2m_9pm_update_200_64_point_tl.jpg

mikeo56

mikeo56 28分前

Smoking in Aussie land .
Up 30 %
Tomorrow in USA will be good.

choo choo trader

choo choo trader 31分前

Thanks for reposting it Striper, somehow I missed it when gdog initially posted it. That is about the most informative video I have seen so far laying out the whole risk/reward story of $NLST.

ron_66271

ron_66271 32分前

No The FDIC and JPM both Had a Claim Against $24 Billion.

Inflated claim of $27*2=$54.00 Billion against the Estate to make WMI as insolvent for the Senior Note holders when JPM controlled the BK process because invested in the Senior Notes of WMI with the takeover.

skitahoe

skitahoe 32分前

Doc, I've been saying this for ages, but not that the full EDEN based facility must be completed. I believe the UK and other countries would simply like to know it's close. They'd like to know the EDEN is making commercial quality vaccine and that it can be delivered in quantity, and they'd like t

FDA-agent-2

FDA-agent-2 36分前

nobody is getting paid here .no editiing or no research which cost money.

Johnnycombat10

Johnnycombat10 37分前

I see both sides of the debate . The company has every right to state their position just as you have your right to speak yours. But you have right to demand anything from anyone on this board. You have no rights other than the right to speak our mind. And I have the to tell you to pound salt. If I

AstroGuru64

AstroGuru64 38分前

The issue still lies with the Treasury Department.

FDA-agent-2

FDA-agent-2 41分前

too much fake news on facebook, yahoo,and youtube these. and tabloid news or censored news.
sites like google, yahoo. facebook cannot get the content for cheap anymore or they won't even license it to them, it used to be free or very cheap to promote their newsight but they don't nobody ever

Truthsocial

Truthsocial 44分前

Vivos Inc. received U.S. FDA approval for the Investigational Device Exemption (IDE) for RadioGel® on July 6, 2026, which permits the initiation of the first-in-human feasibility study at Mayo Clinic in Jacksonville, FL.

While the FDA IDE approval has been granted, the study protocol

gfp927z

gfp927z 44分前

New York Times - >>> In the fourth quarter of 2025, Berkshire Hathaway acquired about 5.1 million shares of The New York Times Company, taking a roughly 3% stake valued at $350–$352 million. This was the first time Berkshire had invested in a newspaper since selling off its holdings in 2020. The mov

uber darthium

uber darthium 44分前

DBSCAM’em

A Linda Poory SCAM for over 2 decades

Can’t wait to read that filing this week

Ought to make for some good SCAM reading

DBSCAM’em

Noted and Always Correct

zerosnoop

zerosnoop 45分前

All the GEMS & FACTS are in the latest 10Q filing. The PROVEN AOT is going GLOBAL.

We are now focusing on a potential sale of 150 units as an initial purchase order under the so-called Laksel LOI (discussed below). This represents a defined India focused initial program wit

gfp927z

gfp927z 46分前

New York Times - >>> In the fourth quarter of 2025, Berkshire Hathaway acquired about 5.1 million shares of The New York Times Company, taking a roughly 3% stake valued at $350–$352 million. This was the first time Berkshire had invested in a newspaper since selling off its holdings in 2020. The mov

raggi65

raggi65 47分前

Do you have a link to the discovery document filed by Quinn Emanuel?
825 pages – that sounds as though there might be plenty of useful arguments in there, and with a citable reference, they would be all the more compelling

juicyjuice10002

juicyjuice10002 50分前

Yes, Executive Order 14393 is widely expected to help Fannie Mae (FNMA) and Freddie Mac (FMCC) by laying the regulatory groundwork for their eventual exit from government conservatorship.

While much of the public text targets community banks, the order contains specific directives fo

Diagnostic Medical Systems

Royal Bank of Canada Cap...

Doubleview Gold

BlackRock Institutional ...

Large Cap Blend Equity

1.571% 21jun2038 1.571% ...

Nickel Industries

Phoenix Education Partners

XBT Provider AB Open End... (GM)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。